July 15, 2026 · The New England journal of medicine · DOI: 10.1056/NEJMoa2600157

Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma

Listen to this summary

This phase 3 trial aimed to determine whether indefinite-duration maintenance therapy with lenalidomide leads to better overall survival compared to fixed-duration therapy (2 years) in patients with standard-risk newly diagnosed multiple myeloma not receiving up-front autologous stem-cell transplantation. The results showed no significant difference in overall survival between the two groups, although progression-free survival was slightly better in the indefinite-duration group. Additionally, the indefinite-duration therapy was associated with a higher incidence of adverse events.

Shaji Kumar, Susanna Jacobus, Adam Cohen, Matthias Weiss, Natalie Callander, Avina Singh, Terri Parker, Michael Green, Raymond Thertulien, Benjamin Parsons, Pankaj Kumar, Prashant Kapoor, Aaron Rosenberg, Elie Dib, Daniel Almquist, Jeffrey Zonder, Edward Faber, Zihan Wei, Kenneth Anderson, Sagar Lonial, Paul Richardson, Robert Orlowski, Lynne Wagner, S Vincent Rajkumar

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play